Released on = March 2, 2007, 1:10 am

Press Release Author = Anna Oderda Creabilis therapeutics SpA

Industry = Biotech

Press Release Summary = COLLERETTO GIACOSA, Feb 28th - Creabilis therapeutics SpA
announced today the appointment of Domenico Criscuolo as Chief Medical Officer,
effective February 21st, 2007.

Press Release Body = Dr Criscuolo graduated in Medicine at the University of Rome
and got a PhD in Haematology and another one in Clinical Oncology. He started
working as Clinical Research physician in 1975 at Lepetit. In 1985 he moved to Roche
Italy as Head of International Clinical Research and Drug Safety, and activated
Phase I-III studies in several therapeutic areas including oncology, inflammation,
CNS, gastroenterology, antimicrobials and antivirals. In 2001 he moved to
Novuspharma - a biotec spin off company of Roche - as Global Head of Clinical
Development, and activated Phase I -III studies on four NCEs in the oncology area.
From 2003 to 2006 he joined the CRO industry, as VP Regional Operations at ICON,
where he established the Italian operations in Milano.
He has been President of SSFA, the Italian association of pharma researchers, and
President of IFAPP, the International Federation of Pharmaceutical Medicine. He is
teacher at Bocconi Business School on Project management and leadership.

Commenting on the announcement, Dr. Silvano Fumero, CEO Creabilis therapeutics,
said: "We are very happy that Dr. Domenico Criscuolo has decided to join our company
as Chief Medical Officer. The most advanced candidate drug entering in phase I in
the next months is CT327, for the topical treatment of psoriasis. The other two
projects approaching clinical stage are CT335/336 for the treatment of Behçet\'s
disease and a mutant Box A (CT500) for HMGB1-RAGE pathologies. The support of
Domenico Criscuolo and his experience in this important phase of the company will be
extremely helpful."

ABOUT CREABILIS THERAPEUTICS:
CREABILIS Therapeutics is a drug discovery and development biotech company, founded
in May 2003 with the aim to discover, select, develop and bring to commercial
fruition novel and highly innovative therapeutic agents.
After three years of research activity a considerable, competitive and diversified
project/product portfolio has been generated. CREABILIS is today strongly committed
to exploit the potential of its discovery assets and to develop its novel
proprietary candidate products.
The most advanced project is related to CT327 in the topical treatment of psoriasis:
a Phase I clinical trial is planned in 2Q 2007.
For more information about Creabilis Therapeutics visit
http://www.creabilistherapeutics.com/


Web Site = http://www.creabilistherapeutics.com

Contact Details = Creabilis therapeutics SpA
Via Ribes 5 10010 Colleretto Giacosa
phone n. +39 0125 53543
fax n. +39 0125 538897
info@creabilistherapeutics.com